0001477932-13-004356.txt : 20130926 0001477932-13-004356.hdr.sgml : 20130926 20130926133156 ACCESSION NUMBER: 0001477932-13-004356 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20130926 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130926 DATE AS OF CHANGE: 20130926 FILER: COMPANY DATA: COMPANY CONFORMED NAME: United Health Products, Inc. CENTRAL INDEX KEY: 0001096938 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 841517723 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27781 FILM NUMBER: 131116406 BUSINESS ADDRESS: STREET 1: 120 WALL STREET STREET 2: SUITE 2401 CITY: NEW YORK STATE: NY ZIP: 10005 BUSINESS PHONE: (646) 961-4459 MAIL ADDRESS: STREET 1: 120 WALL STREET STREET 2: SUITE 2401 CITY: NEW YORK STATE: NY ZIP: 10005 FORMER COMPANY: FORMER CONFORMED NAME: United EcoEnergy Corp. DATE OF NAME CHANGE: 20060224 FORMER COMPANY: FORMER CONFORMED NAME: MNS EAGLE EQUITY GROUP III INC DATE OF NAME CHANGE: 19991019 8-K 1 ueec_8k.htm FORM 8-K ueec_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report: September 26, 2013
 
(Date of earliest event reported: September 26, 2013)

UNITED HEALTH PRODUCTS, INC.
(Exact name of registrant as specified in its charter)

Nevada
  
814-00717
  
84-1517723
(State or other jurisdiction of incorporation)
  
(Commission File Number)
  
(I.R.S. Employer Identification No.)

c/o Morse & Morse, PLLC
1400 Old Country Road, Suite 302
Westbury, NY 11590
 (Address of principal executive offices, zip code)

(516) 487-1452
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

o  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240. 13e-4(c))
 
 
 
 
 
Item 7.01.  Regulation FD Disclosure
 
On September 26, 2013, the Company issued a press release, a copy of which is appended hereto.

Item 9.01.  Financial Statements and Exhibits.
 
Exhibit   Description
     
99.1
  
Press release dated September 26, 2013. (Filed herewith.)
 
 
 
 
 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
UNITED HEALTH PRODUCTS, INC.  
 
 
 
 
Dated: September 26, 2013
 By:
/s/ Dr. Phillip Forman
  
 
 
Dr. Phillip Forman
  
 
 
Chief Executive Officer
  
 
 
 
3
 EX-99.1 2 ueec_ex911.htm PRESS RELEASE ueec_ex911.htm
EXHIBIT 99.1
 
NEWS
 
United Health Products Inc.’s Exclusive Dental Marketing Agent, Sinc Ventures, L.L.C.,
Receives Vendor Status To Supply HemoStyp™ Gauze To Henry Schein, Inc.
 
Westbury, NY – September 26, 2013 - United Health Products, Inc. (OTCQB: UEEC) announced that its HemoStyp™ gauze will be distributed to the dental industry by Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, medical and animal health practitioners. Sinc Ventures, L.L.C., UEEC’s exclusive marketing agent to the US dental industry, directly negotiated the Agreement, and has received vendor status with Henry Schein.
 
HemoStyp is an all-natural product, spun into a gauze which is specifically formulated to help produce hemostasis (blood clotting) almost instantly when positioned on a cut or wound. Once it has completed its task, it is readily dissolved by water or saline solution for easy removal that neither disturbs the clotted surface nor encourages re-bleeding.
 
Dr. Phillip Forman, CEO of United Health Products Inc., stated, "The formulation of our patented HemoStyp gauze is ideal for application in the mouth, which is prone to excessive bleeding due to the vascular nature of the area. This past December The Clinicians Report®, a leading Dental Industry publication, listed HemoStyp among ‘The Best Products Evaluated During 2012.’ This evaluation is evidenced in the dental community through Sinc's Agreement with Henry Schein," Forman concluded.
 
Marcus Mailei, President of Sinc Ventures, said, "The dental industry is a perfect fit for HemoStyp and we are extremely pleased to have the opportunity to work with Henry Schein, a world class organization and a leading distributor of dental products in the US with more than 800 field sales consultants working out of 70+ centers.”
 
About Henry Schein, Inc.
Henry Schein, Inc. is the world's largest provider of health care products and services to office-based dental, medical and animal health practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the NASDAQ 100® Index, Henry Schein offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 25 countries. For more information, visit the Henry Schein Web site at www.henryschein.com.
 
About Sinc Ventures, L.L.C.
Sinc Ventures, L.L.C. is a marketing management and distribution company based in Salt Lake City, Utah, dedicated to becoming a top provider of innovative marketing solutions to its clients through its world-wide publishing network, information technology capabilities, and sales management leadership. For more information, visit http://hemostypdental.com.
 
- Continued-
 
 
1
 
 
About United Health Products, Inc.
United Health Products, Inc. (UEEC) develops, manufactures, and markets a patented hemostatic gauze for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on ramping up sales in its current markets as well as identifying new markets and applications for its product. For more information on United Health Products, Inc., visit: www.unitedhealthproductsinc.com.
 
SAFE HARBOR STATEMENT
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
 
 
Investor Relations Contact:
Terri MacInnis, Dir. of Investor Relations
Bibicoff + MacInnis, Inc.
818.379.8500 terri@bibimac.com
 
 
 
2
GRAPHIC 3 img_ex911001.jpg begin 644 img_ex911001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,# M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_ MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``P`7$#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]%O\`@I%_ MP5]MO^"8W[8OPQT/QM8F]^&/Q%TJX^UWEM'F\T*Y@G1?M``_UL169=R?>&W* MYY4_:7@CQQH_Q+\'Z9X@\/ZG9ZSHFLVZ7=C?6DHE@NHG&5=&'!!%?@]_P>,: MXMS^T#\%M-#`O9^']0N6'<"6YC4?^BC7%_\`!M?_`,%?K[]G#XP:=\"O'NIO M-\/?&EV(="N;B3(\/ZC(<*@)Z03L0I'17*MP&_M(1J37/%=)QBE=+245=+F7O>&LUY,;+#U-FU9]G9:']"OCCQKIGPX\ M'ZGK^M7:6.DZ/;/=W=P^2L4:#+'CD\#H.35K0];M?$FBV>HV4RW%G?PI<02K MRLD;J&5A[$$&OSH_X*\?MPQ>)KI_A9X6N_,L[&;>>$KN32#DY;R0!)#GV$<@0?]YDL[B.:*1XI8F#HZ$JR,#D$$="#7Z7?\`!U?\";SX;?\`!31O%\FY[#XC MZ!97T+XX62UC6SDC'N%AB;_MH*_,ZO\`9[P&^K/P\RE8=WC[%7_Q7?.OE+F1 M^=YK?ZW4OW_X8_4+X%>.+GXF_!KPQKMX[RWVHV*&X8DDR2J2C-[DE<_4U]K_ M`+`/_!1[X$!9V&.*_+_ M`,(?%&\\-_!CPSX:T=WM(++3HTN;D#;-/(V6<`_P+EL<-KE^/.?$C,`0%4KP,\GTK_@M7^TOX]_ M9Z^*7[)EEX*\3ZEX=M?&_P`6+/1-=CM2H74[)XR6@DR#E2?3%<]_P;I_LKW/ MPJ_9NUKXC:K;-!J'Q#N$6Q#KAOL$&X(_T>1I"/4!3WK&_P"#A.01_&/]B-F8 M*!\;+'DG`_U35^\\,?699?"MBY-SG>3OY[>FEM#U_'1Y+2XOQ&6\/4XT\+A5 M&C%1V;@O?;>KD_:.5Y-MNVY^EM?GA_P1:_;CUSQM^SA\?_&GQH^(!N-)\"_% M+7-+BU76ITB@TG3X956*(O@!47=@9]:_0^OP&^&8S_P;]_\`!00'G'Q*\0_^ MEUO7T!^0'Z]?%G_@JK^S=\"M9L=.\7?&[X<:%?ZE;1WEO;W&M0^8\4@#(Y4$ ME0RL"-V,@@]*]A\&?$70OBQX"M_$/A77=*U_1=3@,MGJ6GW27-K,,$;ED0E2 M`>N#P017P-_P20_X(A?L\_#+]@'P%/XG^&/@SX@^*O''AZSUC7M9\1:7%J=Q M=27,"2&*-IE8Q0H&551,#YTF69Y8]#DO(%,\$6XG"%I`!C^&-,DD9H`]O_`."<'[3DW[/W[!+> M)?VB_C]X`\4W5QXOU+3X?%BZ_#/I[9D9H+(3X1?-1$?*8R`IZXKSS_@WG_X* M7VO[5_P+UK0/'?Q"_#WCC0+3XDZ]J,.GZQ9K/_AQX@\7M9:NMFJWZVELC%;1 M9>JQE04P.@8T`?J%^TU^WG\&?V,X;5_BG\2_"'@=[X;K>#5-02.XG'/S+$,N M5R#R%QQ5C]F7]MWX1?MEZ3=7OPL^(OA3QU#8G%RNE7Z336W(&7CX=`2<`E0# M7X8?\$KOVW?V'X_#^J?&O]JWQ59_$3]H[XB:E<:EJC>(?"][J]MX9A$SBWM+ M1#`\*`1A6W)R`P0$!<'-_P""C_[=O['OPI^)/@7]H']C/Q'#X0^-/@[7+<:K MH>@^&[[2M.\6:5(V+F*>(PI"6`QD\;E+9RP0@`_HF\1>)-/\'Z%=ZIJ]_9:7 MIEA&9KF[NYU@@MXP,EW=B%51W)(%>`>!/^"O'[,'Q-^(B>$]"^._PSU'Q#+* M88[1-;A4RN#C8K,0K-GC`))./45\-_MXR7?_``6)_P""K'PG_9EU#5=:TCX' M:+X%M_BAXSTVRN&MI/$;SG_1K61U(8QJ&B'MYDA'S!2/L#XN?\$._P!E3XO_ M``0N?`=Q\$O`6B::]L8+6]T;28;#4].?&%FBN8U$HD!^;+,=Q^\&!((!P/\` MP2T_:2\=_&7]OW]M'POXJ\3:EK>@?#_QO:Z?X=L;@J8M)MV@=FCCP`0I(!YS M7W=7Y`_\&OOP5\0_LX?M`?MC>`?%.MWOB36O!_C*RTF75+N4RSW\<,4R0RNQ M).3$(SC)QT[5^OU`'P9_P2%_:6\>?'3]K[]M/0O%_B?4M?TCX??$L:1X=M;D MJ8])M-LW[F/`&%^5>N>E;/\`P<0_M$^-_P!E7_@DS\1?''P[\1W_`(4\6Z3> M:.EGJ=D5$T"RZI:Q2`;@1\T;LIXZ,:^#OV+?C/\`M2?"S_@H7^W##^SY\(O! M'Q*TV\^*DCZO/KNO'37LIAYXC1%R-X9223VP/6L?_@NW^T3^VW\0?^"8GCW2 MOC+\!/AMX'^'MQ=Z2=2UG2/$YOKNT*ZE;-"%BW'<&F$:$]@Q-`'[>_#3Q(9_ M@WX?UC5KQ%+Z+;7EY=3N$49@5WD=C@`=22>!7@U__P`%I_V3],\?-X8G^/\` M\,EUI9_LQB&L(T0DSC;YH_=]?]K%?G[_`,%_/VP])\/Z3^RM^SYXP\::GX`^ M$WQ)L(=:^(VK::D[W<^DVT4*I9*(59RDS[PVT'E4)!`(-^R_;K_X)$V'P@7P M(GASX?-X<$/DF)_A]?/-AE71U)#*0000<$5YI^TI^W'\'_P!CJSM9_BC\2?"' M@87O-O'JVHQP33CGE(R=[#@C(&,\=:_(O_@A[_P4/\,?LT:[^UK\.O`/BG5_ MB#\!_A5X>N?B)\/KK48+B*2PM47,^GDS*KA1))$HR/X7;^(U[7_P1'_X)E^# M?VN?@?;_`+5W[16C:7\7_BY\:Y)=:BE\10)J%CX?L/-=+>VM;>0&-,(H.=N5 M!"K@`[@#[V\$?\%%_@1\2/A%J'C[0OBWX"U/P?I#QQW^JPZQ"8+%I)!'&)N< MQEG(5=P&2>*^;_\`@J5^U!XZ^$/_``42_88\,>$?%6H:1X8^)?BW5K/Q'96K M+Y.M6\<-FT229!)4>8Y&"/O5\2_\'.'_``1V^''P&_9HE^.?P?T2U^',UOJ= MCI7C+1-"3['I7B"RFND\N22W3$8DCN!$>%`;.2-R@U]&_P#!6;_E)'_P3-_[ M&O5?_233J`)_^"I?_!6GPY\(/V\_V8_#'A+XX>'M&T2#QS=:?\2["VU2'R[: MUCC4>7?9SY:A]PY(Y!]*Z7]N3]O?5+#_`(**?L31_#[XDP#X3_$V]UJ76Y;" M[B;3-:MK>U+*[RG@HC*QR"`"#Z5XE_P69_X)_P#P2M/^"EG['K1_"WP6C_%3 MXC7B^+RNFH#XC#1(["ZX_>9=F;GN36+_`,%T/V!/`?Q;_;8_81^`&F:=#X-^ M'>J:IJVGOI^BH+5+:R58YYX(0O\`J_,59%R.AD)H`_1CPA_P5L_9D\??$B/P MAH_QV^&.H>))IS:QV46O0;Y90<;%8MM8D\``G)Z9KZ'KX9_;/_X(;?LQ^._V M)?%_A/1O@YX$\+7>E:!=3:)J^DZ5%:ZEIMS%"SQ3"Y4>:YWJI;>S;^=V:WO^ M#?\`_:%UC]IW_@D3\&?%'B"^N-3UF/2YM'NKN=V>:Y:RN9;0.['EF(A&3W/- M`'K?_!2SXC:W\'_^"=_QS\6>&M1N-(\1>&O`>M:GIE]!@2V=S#8S212KD$;E M=01D=J_-O]B']BK]MS]JS]C'X=_&70OV\?$UCK/C31(-;M]"U;PG!<6,#R#/ MDRS"4EU[%O)_X#7Z%?\`!709_P""5_[1P)QGX:^(.?\`N'3U^;'_``3,_P"" MDO[6WPV_X)N_"+PO\._V+?$'C?3-,\,6MGHOB.3Q+;6UCJJ`$)<%#AD0]<$@ M^XH`^MO^"0?_``4[\8_'3P7\:?!/[1!\/:!\4OV;=7?3/%VK696WTN^M=LC) M?#^%!B&0MC"XV,`N[:/K?P%^UC\,OBGXTL?#GAKQ[X5U_7M2TE=>MM/L-2BN M+B6P;9MN=BDD1L)$(8XR&&.M?FQ\(?\`@GK\2/V4_P#@F3^VK\5?CA?:1=_& M7X^:!K&O:]8Z6=]EH\26=SY5LK#AF_>N6VY4#8H)VDGE?^"YGGG8):VN6)"6R/]G78H`(CR>:`/ MTC_::_X*4?`7]C7Q#;:/\4/BQX,\&:O=H)8["_OU%T4(R&,2Y=5/8D`'M78? ML[_M4_#?]K;P6WB+X9^-_#?CC1D?RY+G2+U+@0-SA9`#N1C@\,`>*^&_^",7 M_!(GX;Z5^RWX<^,/Q9\/Z1\6?C5\7[%/%/B#Q)XGM8]3F0WBB98(1*&6-%1E M!V@$G/\`#M4>2_\`!3O]F#0_^",_[5'P>_:>^`.F6_@/2/$GBZS\&?$;PMI0 M%OI&O6-X^%E%L/W:2H58C8`-^QN"&W`'ZR?$'XC:!\)O"%[X@\4:WI7AW0]- M3S+K4-2NDM;:W7U:1R%'/')Y/%>+?!C_`(*N?LV_M#^/(_"_@KXV_#OQ#XAG MD$4-A;:O$)[AR!C>QKZD_:Q_X(0?LU?M,_`V[ M\*V/PO\`!_@#6;:W/]@^(_#&E0Z9J6A7*C,4R20A2P5PI*,2K`>N"`#@/^"$ M7[8_BKXP_LG?'7QC\7O&UQJD/@CXL>(M,34]6E2./2M+M8K5UC+8`6.,-([B;HZ..&4^HK\2/^ M"0_@_4_A_P#\&Z/[:WA[7+A[W6M#\1^-=/U">1B[3W$6DVB2.2>2692-XM/_M5]#%T MGVY;3<%\\Q9W>7N(&[&,FL/]H[]KGX8_LA>%(]<^)_CSPQX'TR=BD,VKWR6Y MN&&,B-2=SD9&0H.,BO@:/4+?1/\`@ZP\17]R0D-G\`_.E?;DJBWT;$^O05Y] M_P`$;/V5?#7_``5Y\=?$+]L'X_Z98_$74]7\47N@^!_#^K)]JT?PMIEHRHOE MVSYC:1B<993@H7^\Y-`'Z.?LR?\`!0KX(?MF7-U;_"[XH^#?&UY9`M/::=J" M/=1J.K&$XDVCCYMN.1S7R1_P<6_\%);3]DG]B3Q3I'@+XL:9X.^-%K?Z/-:V M%I?Q+JZVLM[%YK+$V3L:'>2<8V@UT7[=?_!![P+\:/$'AOXB?`DZ)^S]\(_\'2/[(?P_NO\`@F?X MF^*NM>"?"-Y\7(+OP]IUQXIAT]5O2OVV"*1(Y#EUB*LZA23\K8.:`/T.^`W[ M8'PV^,7P%/C71OB'X3UWP]H5LB:SK4&IPM9V,RPH\@FESM0@,"=Q&,BLO]FW M_@I#\!_VP?%M]H'PR^*_@OQIK>FH99[#3=05[A4!P7"'!=0>K*"/>O@;_@M7 M_P`$\&\'_P#!%V/PO^SO\,X;'1WUS2?$OB_PSX0L_LUQKUFD0$[!(QND8;8F M8`,2$S@[:YW]A3P3^P7^WQ^U3\&?''P(OQ\#OB_\(S]HF\%66GIHNH:K$B@2 MVUU&R[;K"^8K21LSE78MQC`!^P]%%%`'P+_P<-?\$V[O]OO]C&34O#%D;SXA M?#9I-7TB&-09=1@V_P"DVB]RSJH91W>-1WK^97X:>"9O%GCFWL9(I%2WDWW0 M92#&JGD'T)/'U-?VR5\3?&__`((!_L_?&_XTZWXZDL_$WAG5?$D_VO4[;0;V M&VL[R;^*0H\+E6K5C)8>;=E1E4T MFWU:2;G"VU3?1NWL<'Y?D#XEPF/XC!UN#'<*8;W7E!R(X MD/S)$W0R''&=N3R/U9^`?_!+/X$?LWW5K>>'?A]I,VJV@_=ZAJ>[4+H'^\&E M+!3_`+H%?05?QMDWA["C45;,)J=OLK;YMZOTLC^RO$SZ8V)S'!SR[A'#RPZF MFG5FU[1)_P`D8MJ+_O.4FNB3LU4T#0;+PKH5EIFFVL-EI^G0);6MO"@2.")% M"JB@=`%``'M7P7_P<6?LL^._CY^QWX3\8_#+1Y/$GCCX'>--/\>V.CQ1EY=4 M2UWB6)5'S,=K[]J\L$P.<5]_T5^F;:(_A^4G)N4G=L_+34?^#K;X%W/P`:ZT M[P_\1+GXSS:;^Z^'G_"-7OVQ=0*X$)G$?E&,2?QABQ4?=W?+7DNE_L3_`!$_ M9L_X-;_C7IOCG1;U?B=\3%OO%^JZ5#`TUY;RWEW`R0NBY/F!%#,O)4L0>0:_ M9)?!>CIKQU4:3I@U0];P6J"X/_`\;NY[UIT$GE7["=I-8?L2_"""XAFMYX?! M>CI)%*ACDC864(*LIP00>"#R*^+OV3_"VJ6?_!Q3^U[JDVF:E#IE]X$T"*VO M)+61;>X=88=RI(1M8CN`3T/H:_2:B@#\YO\`@V`\,:IX3_X)@7EIJVF:CI5V MWCG7Y1!>VLEO*4:X!5MK@'!'0XK#_P"#>KX(-XX_X)G^''U;2/$&DO,TL2RF%'DCF3>5V[6(&%8+MRW='_ M`(*;>,/^"H/[2/@WP)^QMX,?1_A]IU_'?^.OBEXD\'+'I\=B,YM+.&X0%Y7& M2"P5B0N`%#O7ZH:QHEEXBL'M-0M+6^M9/OPW$2RQM]58$&GZ7I5KHEC':V5M M!:6T(Q'#!&(XT'H%'`H`_,[_`(*Q_`[XD_L=_M\_#S]M;X2>#=2^(5GX9T*3 MPE\1?"FE+F_O-'W,ZW5N@Y=X]QR`#CRHCC;N(O\`BS_@Z(^`NK>`7B^'&@?% M'X@?%&\C6'3O`UOX1OK>_:[?Y4BFD:/RD4-]YD=SC.`U?I35&T\+:98:K+?P M:=8PWT^?,N([=%EDSURP&3^)H`_)[_@V3\/?%C3_`(Y?M,?B/^SY;12W?A.9#28;;4/#NCRQR)ONI542/+('4A7P1Y>["[PH^9? MV#O^"D6H_P#!##P2W[,_[6GAOQ7HF@^`Y;B/P3\1-*T>XU/1]?THRN\2OY"L MZ2+N(`"D@?*P4KEOV,JKK&B67B&R:VU"SM;ZW8Y,5Q$LJ'\&!%`'X#?\%W/^ M"H'BK_@JS^S1=^&/V?/AKX_UOX*^#]4L-6\7>,KO0;BUCU*47"1VUK:0NOFN M/,D$C94-\@.T*I)^SO\`@JKX5U76/^"BW_!-RZL]+U.[MM*\4ZI)>S06DDD= MDIM=/`,K*"(P3G[V.A]#7Z86-A!I=I';VT,5O!$,)'$@1$'H`.!4M`'YS_\` M!8[PQJ>N?\%&_P!@NZLM-U&]MM-^(EU+=S6]K)+':(8(P&D900@SW8@=?2JW M_!4[POJFL?\`!9[]@R^M-,U*[L=-UG7'N[F"UDD@M`;,`&1U!5,GIN(S7Z0T M4`21]%O%554LS$P/@`#DGVKXE_P"#7_PSJ7A#_@BU\+M/ MU?3K_2K^&]UPR6UY;O!-&&UB\924 M_M$6=G;W%Y=W7PXU^*&""-I)9G;3YPJJJ@EF).``,FN:_P""(>CWGA[_`()( M_L^V.H6EU8WMKX-LXYK>YB:*6%@IRK*P!!]B*^IZ*`/"/^"HUA<:K_P3>^.] MM:V]Q=W5QX$UB.*&")I996-G*`JJH)9B>``,FOGS]@S]DJ']JW_@W<\`?!WQ M/'>Z+_PF'PU71IS-`T<^GS,K>7(48`[HY`CX(YVU]]44`?D-^P]_P663_@E1 M\)=/_9[_`&RO#?B_P#XD^&,`T?1O%UIHMWJNB>*].B)2WFCE@1VW[`%X4@A1 MDJVY1%\1_BAKW_!Q;^UA\+=$\!>$O%.@?LN_"'Q%!XM\0^+/$&G2:>?%U[`0 M8+.TB<;FCP3DD9PY)"[5#?KCKWAG3?%-HMOJFGV6I0*VX1W4"3(#ZX8$9JS: M6D5A;1P011PPQ*%2.-0JH!T``X`H`_+7]O#PK\1_^"4__!4*]_:[\%^#-;^( M_P`(OB9HMOH'Q0T70X3/JFD/;@+!J,*=+O6U"V>$BZNM,LXFG&0-Z"5B=RY4[3@G%9__!,' M_@N%\/?^":X3<3M/&0,UM?LR_'W5_P#@V]^*_COX0_&/PQXKU/\`9S\5>(KKQ-X#\?Z) MIDNHP:2MPP,MC>QQ`NC)M4_*"<[F`97!7]BP,`#TJ'4-.M]6LI+:[@ANK>8; M9(I4#HX]"#P10!^5_P`:?^"Y?B[_`(*#>)/#_P`+OV$M#\2:[XBUF_@?6OB) MK7AJ6W\/^%M/#?O7*W**7D/`^91P"%W,1CT'_@YD\&Z[K7_!%WQ-I,$6H^)] M;BU3P^LS6=BTD]XZ:A;F240Q`XS@L0HP,U^A6B>'[#PS8+:Z;96FGVRG(AMH M5BC!]=J@"K=`'PO_`,%5_P!I;XW_`+%_[-'P@^)GPKT>[\1>&/"FK6#?$;1; M335O+^ZT1HD$K0J061D(.2N,;P3P#7P9^T/^T)\._P#@L7_P5N_9:U_]ESP7 MXDD\3>`O$<>N>.O'+>'9M(BM=/C>&1K>YD=5,CHJRI\V0QD"*S!J_=NJ>C>' @=/\`#L